Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5633395 | 0.98 | ADRB2 (0.55) | ADRB2NCF1PLD1ADRB1HRH4 | |
| SCHEMBL21186191 | 0.87 | HRH4 (0.50) | HRH4 | |
| Tert-Butyl Formate SCHEMBL27875884 | 0.85 | HRH4 (0.43) | ADRB2NCF1PLD1ADRB1HRH4 | |
| SCHEMBL425041 | 0.83 | HRH4 (0.56) | HRH4 | |
| SCHEMBL15445062 | 0.83 | ADRB2 (0.62) | ADRB2NCF1PLD1ADRB1HRH4 | |
| SCHEMBL30533237 | 0.83 | ADRB1 (0.43) | ADRB2NCF1PLD1ADRB1HRH4 | |
| SCHEMBL9455784 | 0.81 | HRH4 (0.58) | HRH4HTT | |
| Water SCHEMBL28114608 | 0.81 | HRH4 (0.54) | HRH4 | |
| SCHEMBL13027974 | 0.80 | HRH4 (0.61) | HRH4HTTHTR3A | |
| SCHEMBL13131256 | 0.79 | SLC6A2 (0.44) | TP53CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-21 | — | — | US | disclosed |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-25 | — | — | US | disclosed |
| WO-2021123291-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3423436-B1 | PYRIDINYLMETHYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-10730850-B2 | Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-04 | — | — | US | disclosed |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-02-06 | — | — | US | disclosed |
| US-10336729-B2 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| EP-3261638-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| EP-0233051-B1 | ANTIARRHYTHMIC AGENTS | Pfizer Limited (GB) | 1993-09-15 | — | — | EP | disclosed |
| US-4806536-A | Piperazinyl-substituted pyridine and imidazole anti-arrhythmic agents | PFIZER, INC. (US) | 1989-02-21 | — | — | US | disclosed |
| US-4788196-A | Phenyl piperazine anti-arrhythmia agents | PFIZER INC. (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0244115-A2 | Phenyl-piperazine anti-arrhythmia agents | Pfizer Limited (GB) | 1987-11-04 | — | — | EP | disclosed |
| CN-87102873-A | Phenylpiperazine anti-dysrhythmia agents and preparation method thereof | — | 1987-10-28 | — | — | CN | disclosed |
| EP-0233051-A2 | Antiarrhythmic Agents | Pfizer Limited (GB) | 1987-08-19 | — | — | EP | disclosed |
| CN-87100652-A | ANTI-DYSRHYTHMIA AGENTS | — | 1987-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | ADRB2 7/4885NCF1 4069/4885PLD1 1049/4885 |
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | ADRB2 218/4885NCF1 2349/4885PLD1 2971/4885 |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | ADRB2 8/4885NCF1 3621/4885PLD1 1236/4885 |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | ADRB2 8/4885NCF1 3621/4885PLD1 1236/4885 |
| US-10336729-B2 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | AOC3, AOC2, CBR3 | ADRB2 3141/4885NCF1 436/4885PLD1 3949/4885 |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | ADRB2 7/4885NCF1 4069/4885PLD1 1049/4885 |
| US-10730850-B2 | Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | AOC3, XDH, CYP3A43 | ADRB2 2895/4885NCF1 381/4885PLD1 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.